Hemosol (NASDAQ:HMSL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Hemosol Charts. Click Here for more Hemosol Charts.](/p.php?pid=staticchart&s=N%5EHMSL&p=8&t=15)
Hemosol Receives Extension from NASDAQ to Regain Compliance With
Listing Requirements
TORONTO, Dec. 21 /PRNewswire-FirstCall/ -- Hemosol Corp. (NASDAQ:HMSLNASDAQ:
TSX:NASDAQ:HML) today announced that it received from NASDAQ an additional 180
day extension (to June 16, 2005) to regain compliance with NASDAQ's minimum bid
price requirement. The notice of the 180-day extension follows an initial
notice from NASDAQ on June 21, 2004 that the Company had until December 20,
2004 to regain compliance with NASDAQ's minimum bid price requirement and that
the Company may qualify as of such date for an additional 180 day extension of
the compliance period.
About Hemosol
Hemosol is a biopharmaceutical company focused on the development and
manufacturing of biologics, particularly blood-related proteins. Hemosol has a
broad range of novel therapeutic products in development, including oxygen
therapeutics and protein-based therapeutics to treat certain infectious
diseases, cancers and anemia.
For more information visit Hemosol's website at http://www.hemosol.com/.
Hemosol's common shares are listed on the NASDAQ Stock Market under the trading
symbol "HMSL" and on the Toronto Stock Exchange under the trading symbol "HML".
Certain statements concerning Hemosol's future prospects are "forward- looking
statements" within the meaning of the United States Private Securities
Litigation Reform Act of 1995 and other applicable securities legislation.
There can be no assurances that future results will be achieved, and actual
results could differ materially from forecasts and estimates. Important factors
that could cause actual results to differ materially from forecasts and
estimates include, but are not limited to: Hemosol's ability to successfully
implement the Cascade technology and commercialize products derived therefrom;
Hemosol's ability to obtain additional financing; Hemosol's ability to obtain
regulatory approvals for its products; Hemosol's ability to successfully
complete clinical trials for its products; Hemosol's ability to enter into
satisfactory arrangements for the supply of materials used in its manufacturing
operations and the sale of resulting products to customers; technical,
manufacturing or distribution issues; the competitive environment for Hemosol's
products and services; the degree of market penetration of Hemosol's products;
Hemosol's ability to attract and retain clients for its bio-manufacturing
services; and other factors set forth in filings with Canadian securities
regulatory authorities and the U.S. Securities and Exchange Commission. These
risks and uncertainties, as well as others, are discussed in greater detail in
the filings of Hemosol with Canadian securities regulatory authorities and the
U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise
or update any forward-looking statements in order to reflect events or
circumstances after the date any such statement is made.
DATASOURCE: Hemosol Corp.
CONTACT: Jason Hogan, Investor & Media Relations, (416) 361-1331,
800-789-3419, (416) 815 0080 fax, , http://www.hemosol.com/;
Archived images on this organization are available through CNW E-Pix at
http://www.newswire.ca/. Images are free to members of The Canadian Press.
To request a free copy of this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.